Размер шрифта
-
+

С ума сойти! Путеводитель по психическим расстройствам для жителя большого города

Сноски

Комментарии

1

Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15–4927, NSDUH Series H-50). Retrieved from http://www.samhsa.gov/data/

2

Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM – IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 2005 Jun; 62(6): 617–27.

3

Lenzenweger MF, Lane MC, Loranger AW, Kessler RC (2007). DSM – IV personality disorders in the National Comorbidity Survey Replication. Biological Psychiatry, 62(6), 553–564.

4

Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto mental and addictive disorders service system. Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry. 1993 Feb; 50(2): 85–94.

5

Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15–4927, NSDUH Series H-50). Retrieved from http://www.samhsa.gov/data/

7

Kessler RC, Angermeyer M, Anthony Jc, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry. 2007; 6(3): 168–176.

9

Marazziti D, Akiskal HS, Rossi A, Cassano GB. Alteration of the platelet serotonin transporter in romantic love. Psychol Med. 1999 May; 29(3): 741–5.

10

Bentall RP. A proposal to classify happiness as a psychiatric disorder. Journal of Medical Ethics. 1992; 18(2): 94–98.

12

Dima D, Roiser JP, Dietrich DE, Bonnemann C, Lanfermann H, Emrich HM, Dillo W. Understanding why patients with schizophrenia do not perceive the hollow-mask illusion using dynamic causal modelling. Neuroimage. 2009 Jul 15; 46(4): 1180–6. doi: 10.1016/j.neuroimage.2009.03.033.Epub 2009 Mar 24.

13

Rosenhan DL. On being sane in insane places. Science. 1973 Jan 19; 179(4070): 250–8.

14

Progler Y. Mental illness and social stigma: notes on "How Mad Are You?" Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2009; 14(5): 331–334.

15

Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord. 2009. Se; 117(1–2): 1–17.

16

Contribution of depression to cognitive impairment and dementia in older adults. Neurologist. 2007 May; 13(3): 105–17.

17

American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.). Arlington, VA: American Psychiatric Publishing, p. 20. ISBN978–0–89042–555–8.

18

Dalgleish T. The emotional brain. Nat Rev Neurosci. 2004 Jul; 5(7): 583–9. Review.

19

Mega MS, Cummings JL, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci. 1997 Summer; 9(3): 315–30. Review.

20

Robert Sapolsky (2005). "Biology and Human Behavior: The Neurological Origins of Individuality, 2nd edition". The Teaching Company, p. 13 & 14 of Guide Book.

21

Nichols DE. Hallucinogens. Pharmacol Ther. 2004 Feb; 101(2): 131–81. Review.

22

Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003 Jun; 63(6): 1223–9.

23

Kennett GA, Ainsworth K, Trail B, Blackburn TP. BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology. 1997 Feb; 36(2): 233–9.

24

Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5; 102(23): 2836–41.

25

de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 Apr; 26(2): 137–44. Review.

26

Hofmann A. (1983). LSD, my problem child: Reflections on sacred drugs, mysticism, and science. Los Angeles: J. P. Tarcher. P. 21.

27

Andersson A, Wiréhn A-B, Ölvander C, Ekman DS, Bendtsen P. Alcohol use among university students in Sweden measured by an electronic screening instrument. BMC Public Health. 2009;9:229. doi: 10.1186/1471-2458-9-229.

28

Kellett J, Kokkinidis L. Extinction deficit and fear reinstatement after electrical stimulation of the amygdala: implications for kindling-associated fear and anxiety. Neuroscience. 2004; 127(2): 277–87.

29

Ghaemi SN. The rise and fall of the biopsychosocial model. Br J Psychiatry. 2009 Jul; 195(1): 3–4. doi: 10.1192/bjp.bp.109.063859.

30

Haygarth, John. (1800). Of the imagination, as a cause and as a cure of disorders of the body; exemplified by fictitious tractors, and epidemical convulsions. Read to the Literary and Philosophical Society of Bath. By John Haygarth, M.D. … Bath: printed by R. Cruttwell; and sold by Cadell and Davies, London.

31

Beecher HK. The powerful placebo. J Am Med Assoc. 1955; 159(17): 1602–6.

32

Howick J, Friedemann C, Tsakok M, et al. Are treatments more effective than placebos? A systematic review and meta-analysis. PLoS ONE. 2013; 8(5): e62599.

33

Linde K, Fässler M, Meissner K. Placebo interventions, placebo effects and clinical practice. Philos Trans R Soc Lond, B, Biol Sci. 2011; 366(1572): 1905–12.

34

Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008; 65(2): 220–31.

35

Oken BS. Placebo effects: clinical aspects and neurobiology. Brain. 2008; 131(Pt 11): 2812–23.

36

Matre D, Casey KL, Knardahl S. Placebo-induced changes in spinal cord pain processing. J Neurosci. 2006; 26(2): 559–63.

37

Qiu YH, Wu XY, Xu H, Sackett D. Neuroimaging study of placebo analgesia in humans. Neurosci Bull. 2009; 25(5): 277–82.

38

Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci. 2009; 1156: 198–210.

39

Lidstone SC, Stoessl AJ. Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol. 2007; 9(4): 176–85.

40

Misra S. Randomized double blind placebo control studies, the "Gold Standard" in intervention based studies. Indian Journal of Sexually Transmitted Diseases. 2012; 33(2): 131–134.

41

Levine R. A Real Mental Ward Becomes A Movie 'Cuckoo's Nest'. The New York Times. April 13, 1975. http://www.nytimes.com/packages/html/movies/bestpictures/cuckoo-ar1.html. Accessed Feb 25, 2016.

42

Tooth GC, and Newton, MP: Leukotomy in England and Wales 1942–1954. London, Her Majesty's Stationary Office, 1961.

43

Jansson B. Controversial Psychosurgery Resulted in a Nobel Prize. Nobel Media AB2014. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1949/moniz-article.html. Accessed Feb 25, 2016.

44

Soares MS, Paiva WS, Guertzenstein EZ, et al. Psychosurgery for schizophrenia: history and perspectives. Neuropsychiatric Disease and Treatment. 2013; 9: 509–515.

46

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003; 361(9360): 799–808.

47

Fitzgerald PB. Non-pharmacological biological treatment approaches to difficult-to-treat depression. Med J Aust. 2013; 199(6 Suppl): 48–51.

48

Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. 2nd ed. Washington, DC: American Psychiatric Publishing, 2001.

49

MacQueen G, Parkin C, Marriott M, Bégin H, Hasey G. The long-term impact of treatment with electroconvulsive therapy on discrete memory systems in patients with bipolar disorder. Journal of Psychiatry & Neuroscience. 2007; 32(4): 241–249.

50

Coentre R, Barrocas D, Chendo I, et al. [Electroconvulsive therapy: myths and evidences]. Acta Med Port. 2009; 22(3): 275–80.

51

Cristancho MA, Alici Y, Augoustides JG, O'reardon JP. Uncommon but serious complications associated with electroconvulsive therapy: recognition and management for the clinician. Curr Psychiatry Rep. 2008; 10(6): 474–80.

52

Wilkins KM, Ostroff R, Tampi RR. Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature. J Geriatr Psychiatry Neurol. 2008; 21(1): 3–11.

53

Golenkov A, Ungvari GS, Gazdag G. Public attitudes towards electroconvulsive therapy in the Chuvash Republic. Int J Soc Psychiatry. 2012; 58(3): 289–94.

54

Martin CD. Ernest Hemingway: a psychological autopsy of a suicide. Psychiatry. 2006; 69(4): 351–61.

55

Swartz C. Electroconvulsive and Neuromodulation Therapies. Cambridge University Press; 2009. P. 185–187.

56

Leopold T. (2016, November 18), Sam Phillips, Elvis and the invention of rock 'n' roll, CNN, Available at: http://edition.cnn.com/2015/11/18/entertainment/sam-phillips-sun-records-guralnick-feat/. Accessed February 24, 2016.

57

Rawsthorn A. Yves Saint Laurent, a biography. Nan A. Talese; 1996.

58

The Atlantic Monthly; January 1996; Bud's Bubble; Volume 277, No. 1; pages 99–102.

59

Gardiner H. & Carey B., Researchers Fail to Reveal Full Drug Pay, The New York Times, Jun 8, 2008.

60

Мартынихин И. О состоянии стационарных психиатрических учреждений РФ, Российское общество психиатров (6 декабря 2013 год, 09:35). http://psychiatr.ru/news/192

Страница notes